AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37161775 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 758
Study 37161796 — intervention group
Group type: COMPARATOR
Intervention: DASH diet (serum)
Number of subjects: 614
Study 37161796 — intervention group
Group type: COMPARATOR
Intervention: DASH high-sodium diet (urine)
Number of subjects: 614
Study 37161796 — intervention group
Group type: COMPARATOR
Intervention: DASH low-sodium diet (urine)
Number of subjects: 614
Study 37161823 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Lipid-Lowering Therapies
Number of subjects: 0
Study 37162000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application designed to support patients with insulin therapy
Number of subjects: 32
Study 37162000 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 32
Study 37162147 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg of plecanatide
Number of subjects: 2639
Study 37162147 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of plecanatide
Number of subjects: 2639
Study 37162147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2639
Study 37162238 — intervention group
Group type: EXPERIMENTAL
Intervention: ZILVER PTX stent
Number of subjects: 220
Study 37162238 — intervention group
Group type: COMPARATOR
Intervention: Bypass surgery
Number of subjects: 220
Study 37162250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (four-week trimodal programme: exercise, nutritional intervention, anxiety reduction)
Number of subjects: 250
Study 37162250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation (four-week trimodal programme)
Number of subjects: 250
Study 37162250 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Number of subjects: 250
Study 37162301 — intervention group
Group type: EXPERIMENTAL
Intervention: Recreational team handball exercise programme
Number of subjects: 54
Study 37162301 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 54
Study 37162349 — intervention group
Group type: EXPERIMENTAL
Intervention: Vancomycin intravenously
Number of subjects: 14
Study 37162349 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based simulations of various infusion modes
Number of subjects: 14
Study 37162539 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic modified Broström procedure
Number of subjects: 64
Study 37162539 — intervention group
Group type: COMPARATOR
Intervention: Open modified Broström procedure
Number of subjects: 64
Study 37162595 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotypes with prominent geriatric features
Number of subjects: 1268
Study 37162595 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenotype representing the oldest old patients with low severity of the critical condition
Number of subjects: 1268
Study 37162595 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression models combining phenotype, ventilatory support, and country
Number of subjects: 1268
Study 37162595 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisions to withhold LST
Number of subjects: 1268
Study 37162595 — intervention group
Group type: EXPERIMENTAL
Intervention: Decisions to withdraw LST
Number of subjects: 1268
Study 37162700 — intervention group
Group type: COMPARATOR
Intervention: Cognitive training and physical exercise (control)
Number of subjects: 0
Study 37162700 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 37162744 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 200 mg every 4 weeks until week 24
Number of subjects: 101
Study 37162744 — intervention group
Group type: COMPARATOR
Intervention: Placebo every 4 weeks until week 24
Number of subjects: 101
Study 37162745 — intervention group
Group type: EXPERIMENTAL
Intervention: Convalescent plasma
Number of subjects: 24861
Study 37162923 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 infection during pregnancy
Number of subjects: 2300
Study 37163146 — intervention group
Group type: EXPERIMENTAL
Intervention: EZC Pak
Number of subjects: 360
Study 37163146 — intervention group
Group type: EXPERIMENTAL
Intervention: EZC Pak + Vitamin D
Number of subjects: 360
Study 37163146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 360
Study 37163204 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Release Technique (PRT)
Number of subjects: 72
Study 37163204 — intervention group
Group type: COMPARATOR
Intervention: Sham PRT (Control)
Number of subjects: 72
Study 37163222 — intervention group
Group type: EXPERIMENTAL
Intervention: Rilonacept (Arcalyst)
Number of subjects: 0
Study 37163222 — intervention group
Group type: EXPERIMENTAL
Intervention: Anakinra (Kineret)
Number of subjects: 0
Study 37163240 — intervention group
Group type: EXPERIMENTAL
Intervention: Closure of mesenteric defects
Number of subjects: 2507
Study 37163240 — intervention group
Group type: COMPARATOR
Intervention: Nonclosure
Number of subjects: 2507
Study 37163249 — intervention group
Group type: EXPERIMENTAL
Intervention: Specialist palliative care intervention
Number of subjects: 235
Study 37163249 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 235
Study 37163331 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard implementation intervention (multimodal training for coaches, organizational strategy meetings)
Number of subjects: 72
Study 37163331 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced implementation intervention (includes all standard strategies plus performance coaching)
Number of subjects: 72
Study 37163341 — intervention group
Group type: EXPERIMENTAL
Intervention: Immersive telemedicine platform for diabetes medical group visits (DMGVs)
Number of subjects: 309
Study 37163341 — intervention group
Group type: COMPARATOR
Intervention: In-person (IP) diabetes medical group visits (DMGVs)
Number of subjects: 309
Study 37163342 — intervention group
Group type: EXPERIMENTAL
Intervention: Sensor-Controlled Digital Game (SCDG)
Number of subjects: 200
Study 37163342 — intervention group
Group type: COMPARATOR
Intervention: Sensor-only group (control)
Number of subjects: 200
Study 37163349 — intervention group
Group type: EXPERIMENTAL
Intervention: PTCy, abatacept, and a short course of tacrolimus (CAST)
Number of subjects: 46
Study 37163350 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Oriented Music Intervention (POMI) using music based on patient preferences via headphones or music pillow for 20-30 minutes
Number of subjects: 24
Study 37163350 — intervention group
Group type: COMPARATOR
Intervention: Control intervention (headphones or pillow without music)
Number of subjects: 24
Study 37163358 — intervention group
Group type: EXPERIMENTAL
Intervention: Carfilzomib, daratumumab, and dexamethasone (KdD)
Number of subjects: 0
Study 37163360 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthracycline-based regimens
Number of subjects: 211
Study 37163360 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Radiotherapy (RT)
Number of subjects: 211
Study 37163360 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone (RT)
Number of subjects: 211
Study 37163360 — intervention group
Group type: EXPERIMENTAL
Intervention: SALENTO Model (Limited Stage Peripheral T-Cell Lymphoma Prognostic Model)
Number of subjects: 211
Study 37163435 — intervention group
Group type: COMPARATOR
Intervention: VAN-Visual Network (VN) connectivity in normal cognition (NC) group (n = 106)
Number of subjects: 139
Study 37163435 — intervention group
Group type: COMPARATOR
Intervention: VAN-Visual Network (VN) connectivity in cognitive non-decline (CND) group (n = 113)
Number of subjects: 139
Study 37163435 — intervention group
Group type: EXPERIMENTAL
Intervention: VAN-VN connectivity
Number of subjects: 139
Study 37163435 — intervention group
Group type: EXPERIMENTAL
Intervention: VAN-VN connectivity in normal cognition participants
Number of subjects: 139
Study 37163621 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab
Number of subjects: 926
Study 37163621 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-obinutuzumab-ibrutinib
Number of subjects: 926
Study 37163621 — intervention group
Group type: COMPARATOR
Intervention: Chemoimmunotherapy
Number of subjects: 926
Study 37163621 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-rituximab
Number of subjects: 926
Study 37163622 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy delivered by means of a peanut patch for 12 months
Number of subjects: 362
Study 37163622 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered daily for 12 months
Number of subjects: 362
Study 37163622 — intervention group
Group type: EXPERIMENTAL
Intervention: Epicutaneous immunotherapy delivered by means of a peanut patch
Number of subjects: 362
Study 37163623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib (40 mg daily) plus nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Number of subjects: 855
Study 37163623 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (3 mg/kg) and ipilimumab (1 mg/kg)
Number of subjects: 855
Study 37163623 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabozantinib plus nivolumab and ipilimumab
Number of subjects: 855
Study 37163623 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab and ipilimumab
Number of subjects: 855
Study 37163686 — intervention group
Group type: EXPERIMENTAL
Intervention: Buzzy device
Number of subjects: 300
Study 37163686 — intervention group
Group type: COMPARATOR
Intervention: EMLA cream
Number of subjects: 300
Study 37163774 — intervention group
Group type: EXPERIMENTAL
Intervention: Rezivertinib (≥180 mg orally once daily)
Number of subjects: 355
Study 37164012 — intervention group
Group type: EXPERIMENTAL
Intervention: BNT162b4 (mRNA vaccine targeting conserved non-spike antigens)
Number of subjects: 0
Study 37164012 — intervention group
Group type: COMPARATOR
Intervention: BNT162b2 (spike-protein-encoding vaccine)
Number of subjects: 0
Study 37164298 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-component intervention including oncology clinic-based oncofertility needs screen, women's health survivorship care plan in Spanish and English, remote patient navigation, telehealth oncofertility consultation.
Number of subjects: 135
Study 37164298 — intervention group
Group type: COMPARATOR
Intervention: Usual care during the pre-intervention period (12 months).
Number of subjects: 135
Study 37164457 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up by a community-based stroke coordinator who identifies individual risk profiles and sets up action plans based on individual goals.
Number of subjects: 300
Study 37164457 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly follow-up by a community-based stroke coordinator.
Number of subjects: 300
Study 37164457 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 300
Study 37164461 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent provider-patient intervention (patient mHealth app, provider dashboard, continuous glucose monitoring, community health worker, team-based care)
Number of subjects: 124
Study 37164461 — intervention group
Group type: COMPARATOR
Intervention: Current standard of diabetes and prenatal care
Number of subjects: 124
Study 37164465 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 266
Study 37164465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 266
Study 37164467 — intervention group
Group type: EXPERIMENTAL
Intervention: Low iodine (20 µg/day) multivitamin and mineral supplement
Number of subjects: 754
Study 37164467 — intervention group
Group type: COMPARATOR
Intervention: Identical supplement containing 200 µg/day
Number of subjects: 754
Study 37164469 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurological and cognitive impairments assessed using validated clinical assessment methods
Number of subjects: 500
Study 37164469 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood samples for biomarker measuring (protein, RNA and DNA)
Number of subjects: 500
Study 37164469 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical variables registered at baseline and each follow-up visit
Number of subjects: 500
Study 37164469 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of recurrent stroke and other major vascular events
Number of subjects: 500
Study 37164472 — intervention group
Group type: EXPERIMENTAL
Intervention: GBDPs group (treatment group)
Number of subjects: 72
Study 37164472 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (control group)
Number of subjects: 72
Study 37164478 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic ankle instability at 12-month follow-up
Number of subjects: 0
Study 37164478 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost diary containing direct and indirect costs related to their injury
Number of subjects: 0
Study 37164490 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge translation program of guidelines
Number of subjects: 45193
Study 37164490 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45193
Study 37164620 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise training (HBET) programme
Number of subjects: 50
Study 37164620 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (CONTROL)
Number of subjects: 50
Study 37164838 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 100 mg
Number of subjects: 40
Study 37164838 — intervention group
Group type: EXPERIMENTAL
Intervention: Inclisiran 300 mg
Number of subjects: 40
Study 37164838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 37164837 — intervention group
Group type: COMPARATOR
Intervention: Volanesorsen
Number of subjects: 3
Study 37164948 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitravatinib plus nivolumab
Number of subjects: 20
Study 37164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ansofaxine 80 mg/day
Number of subjects: 588
Study 37164957 — intervention group
Group type: EXPERIMENTAL
Intervention: Ansofaxine 160 mg/day
Number of subjects: 588
Study 37164957 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 588
Study 37164959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91
Study 37164959 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal followed by intramuscular administration of NDV-HXP-S vaccine
Number of subjects: 91
Study 37165291 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasburicase 0.20 mg/kg/day
Number of subjects: 50
Study 37165331 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership training comprising five full day modules and four smaller group-training sessions over a period of 5 months.
Number of subjects: 200
Study 37165331 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention).
Number of subjects: 200
Study 37165331 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership training intervention.
Number of subjects: 200
Study 37165382 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension plus practice facilitation (experimental condition)
Number of subjects: 960
Study 37165382 — intervention group
Group type: COMPARATOR
Intervention: Hypertension program only (usual care)
Number of subjects: 960
Study 37165406 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Arousal Reappraisal (SAR)
Number of subjects: 200
Study 37165406 — intervention group
Group type: EXPERIMENTAL
Intervention: Worked Examples (WE)
Number of subjects: 200
Study 37165406 — intervention group
Group type: COMPARATOR
Intervention: Control group for SAR
Number of subjects: 200
Study 37165406 — intervention group
Group type: COMPARATOR
Intervention: Control group for WE
Number of subjects: 200
Study 37165413 — intervention group
Group type: COMPARATOR
Intervention: Median benchmark, benefit framing
Number of subjects: 267
Study 37165413 — intervention group
Group type: COMPARATOR
Intervention: Top quartile benchmark, benefit framing
Number of subjects: 267
Study 37165413 — intervention group
Group type: COMPARATOR
Intervention: Median benchmark, risk framing
Number of subjects: 267
Study 37165413 — intervention group
Group type: COMPARATOR
Intervention: Top quartile benchmark, risk framing
Number of subjects: 267
Study 37165711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual weaning of EVD treatment (multi-step increase of resistance over days)
Number of subjects: 244
Study 37165711 — intervention group
Group type: COMPARATOR
Intervention: Prompt closure of EVD treatment
Number of subjects: 244
Study 37165711 — intervention group
Group type: EXPERIMENTAL
Intervention: Gradual weaning of EVD treatment
Number of subjects: 244
Study 37165841 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37165840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinpentraxin alfa (RO7490677, PRM-151) administered intravenously weekly (QW) or every 4 weeks (Q4W)
Number of subjects: 27
Study 37165840 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinpentraxin alfa
Number of subjects: 27
Study 37165867 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 37165869 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive SBP intervention (<120 mm Hg)
Number of subjects: 8298
Study 37165869 — intervention group
Group type: COMPARATOR
Intervention: Standard SBP intervention (<140 mm Hg)
Number of subjects: 8298
Study 37165897 — intervention group
Group type: EXPERIMENTAL
Intervention: Assessment of RNA splicing in CHD cases with splice-altering variants
Number of subjects: 4472
Study 37165901 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravascular ultrasound (IVUS) assessment
Number of subjects: 82
Study 37165901 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical coherence tomography (OCT)
Number of subjects: 82
Study 37165901 — intervention group
Group type: EXPERIMENTAL
Intervention: Index of microcirculatory resistance measurements
Number of subjects: 82
Study 37165930 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX-102 SL 2.8 mg for 2 weeks, followed by 5.6 mg for 12 weeks
Number of subjects: 503
Study 37165930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 503
Study 37165930 — intervention group
Group type: EXPERIMENTAL
Intervention: TNX-102 SL
Number of subjects: 503
Study 37165977 — intervention group
Group type: EXPERIMENTAL
Intervention: Septal myectomy for HOCM
Number of subjects: 56
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: HINTS (for clinicians trained in its use) in patients with nystagmus
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Finger rub
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of gait unsteadiness
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain computed tomography (CT)
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine magnetic resonance imaging (MRI)
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Search for symptoms or signs of cerebral ischemia
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: CT
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: CT angiography or MRI angiography
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Dix-Hallpike test
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term steroids
Number of subjects: 0
Study 37166022 — intervention group
Group type: EXPERIMENTAL
Intervention: Epley maneuver
Number of subjects: 0
Study 37166053 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP503 (NBTXR3) nanoparticles with radiotherapy and concurrent chemotherapy
Number of subjects: 0
Study 37166053 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (preoperative concurrent chemoradiotherapy)
Number of subjects: 0
Study 37166151 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D supplementation (600 mg of calcium plus 200 UI of cholecalciferol)
Number of subjects: 56
Study 37166199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 692
Study 37166242 — intervention group
Group type: EXPERIMENTAL
Intervention: Under-the-nose face mask (FM)
Number of subjects: 108
Study 37166242 — intervention group
Group type: COMPARATOR
Intervention: Over-the-nose face mask (FM)
Number of subjects: 108
Study 37166242 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 108
Study 37166257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 1 mg/kg
Number of subjects: 160
Study 37166257 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 0.3 mg/kg
Number of subjects: 160
Study 37166385 — intervention group
Group type: EXPERIMENTAL
Intervention: Tildrakizumab 100 mg at Week 0, Week 4, and every 12 weeks thereafter
Number of subjects: 55
Study 37166484 — intervention group
Group type: EXPERIMENTAL
Intervention: Tislelizumab + DNA hypomethylating agent (HMA) + CAG regimen
Number of subjects: 27
Study 37166557 — intervention group
Group type: EXPERIMENTAL
Intervention: High baseline ctDNA CNA burden
Number of subjects: 672
Study 37166557 — intervention group
Group type: COMPARATOR
Intervention: pCR(+) and low I-score
Number of subjects: 672
Study 37166557 — intervention group
Group type: COMPARATOR
Intervention: non-pCR and high I-score
Number of subjects: 672
Study 37166557 — intervention group
Group type: EXPERIMENTAL
Intervention: LP-WGS ctDNA CNA analysis
Number of subjects: 672
Study 37166557 — intervention group
Group type: EXPERIMENTAL
Intervention: ctDNA CNA burden
Number of subjects: 672
Study 37166675 — intervention group
Group type: EXPERIMENTAL
Intervention: MG Symptoms Patient-Reported Outcome (PRO)
Number of subjects: 43
Study 37166675 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantitative MG (QMG)
Number of subjects: 43
Study 37166675 — intervention group
Group type: EXPERIMENTAL
Intervention: MG Composite (MGC)
Number of subjects: 43
Study 37166675 — intervention group
Group type: EXPERIMENTAL
Intervention: MG-Activities of Daily Living (MG-ADL)
Number of subjects: 43
Study 37166675 — intervention group
Group type: EXPERIMENTAL
Intervention: MG Symptoms PRO
Number of subjects: 43
Study 37166675 — intervention group
Group type: EXPERIMENTAL
Intervention: Rasch model analyses
Number of subjects: 43
Study 37166786 — intervention group
Group type: EXPERIMENTAL
Intervention: Swab pressing
Number of subjects: 126